Clinical trial readout dates for CG Oncology, Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
| Phase 2 Cretostimogene Grenadenorepvec High-Risk Non-Muscle-Invasive Bladder Cancer · NCT06567743 | March 2027 Recruiting |
| Phase 3 Cretostimogene Grenadenorepvec Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer · NCT04452591 | June 2030 Ongoing |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 3 Cretostimogene Grenadenorepvec Non Muscle Invasive Bladder Cancer; Urologic Cancer · NCT06111235 | November 2026 Ongoing |
CG Oncology, Inc. reported $984M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-06). Its net loss for that quarter was $57M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-11-16 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-06 |